Design and Synthesis of Novel Dimeric Morphinan Ligands for κ and μ Opioid Receptors
- 25 October 2003
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 46 (24) , 5162-5170
- https://doi.org/10.1021/jm030139v
Abstract
A novel series of morphinans were synthesized, and their binding affinity at and functional selectivity for μ, δ, and κ opioid receptors were evaluated. These dimeric ligands can be viewed as dimeric morphinans, which were formed by coupling two identical morphinan pharmacophores (cyclorphan (1) or MCL 101 (2)) with varying connecting spacers. Ligands 6 and 7 with alkyl spacers on the nitrogen position and ligands 8 and 9 in which the two morphinan pharmacophores were coupled by ether moieties at the 3-hydroxyl positions showed significant decrease in affinity at all three opioid receptors. An improvement in the affinity was achieved by introducing an ester moiety as the spacer in the dimeric morphinans. It was observed that the affinity of these ligands was sensitive to the character and length of the spacer. Compound 13 (MCL-139) with a 4-carbon ester spacer, compound 17 (MCL-144) containing a 10-carbon spacer, and compound 19 (MCL-145) with the conformationally constrained fumaryl spacer were the most potent ligands in this series, displaying excellent affinities at μ and κ receptors (Ki = 0.09−0.2 nM at μ and Ki = 0.078−0.049 nM at κ), which were comparable to the parent compound 2. Ligand 12, a compound containing only one morphinan pharmacophore and a long-chain ester group, had affinity at both μ and κ receptors almost identical to that of the parent ligand 2. In the [35S]GTPγS binding assay, ligands 13, 17, and 19 and their parent morphinans 1 and 2 stimulated [35S]GTPγS binding mediated by the μ and κ receptors. Compounds 13 and 17 were full κ agonists and partial μ agonists, while compound 19 was a partial agonist at both μ and κ receptors. These novel ligands, as well as their interesting pharmacological properties, will serve as the basis for our continuing investigation of the dimeric ligands as potential probes for the pharmacotherapy of cocaine abuse and may also open new avenues for the characterization of opioid receptors.Keywords
This publication has 19 references indexed in Scilit:
- Effects of Mixed-Action κ/μ Opioids on Cocaine Self-Administration and Cocaine Discrimination by Rhesus MonkeysNeuropsychopharmacology, 2002
- Mixed κ agonists and μ agonists/Antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinanBioorganic & Medicinal Chemistry Letters, 2001
- Opioids and Their Complicated Receptor ComplexesNeuropsychopharmacology, 2000
- Oligomerization of μ- and δ-Opioid ReceptorsJournal of Biological Chemistry, 2000
- Dimerization of the δ Opioid Receptor:Journal of Biological Chemistry, 1997
- Cyclazocine revisitedNeurochemical Research, 1996
- Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonistsTrends in Pharmacological Sciences, 1989
- Synthesis and biological activity of analogs of .beta.-chlornaltrexamine and .beta.-funaltrexamine at opioid receptorsJournal of Medicinal Chemistry, 1986
- Narcotic antagonistic potency of bivalent ligands which contain .beta.-naltrexamine. Evidence for simultaneous occupation of proximal recognition sitesJournal of Medicinal Chemistry, 1982
- Comments on the optical and radio detection of black hole explosionsNature, 1977